Welcome @AmoebaNature as a featured exhibitor at the BioSolutions Conference & Expo!

Amoéba is an innovative #greentech company providing the industry with disruptive & sustainable solutions for key resource treatment. Learn more at


📣 Communiqué de presse :
#Amoéba annonce l’annulation de l’émission de la 8° tranche optionnelle d’OCA et la signature d’un contrat avec Redbridge Debt and Treasury Advisory afin d’adapter sa stratégie financière aux enjeux de transformation industrielle

📣 Communiqué de presse :
#Amoéba confirme son éligibilité au dispositif PEA-PME. Les #actions AMOEBA peuvent donc être intégrées dans les portefeuilles PEA PME, dédiés aux #investissements dans les #PME et #ETI selon les critères réglementaires.

🎥 @Fabrice Plasson, PDG d’#Amoéba, revient sur cette année exceptionnelle dans une vidéo dédiée au #bilan 2022 et aux #perspectives 2023. AMM, nouvelle usine, stratégie, plan de financement, tant de sujets abordés sur la chaîne #YouTube d’#Amoéba :

Postponement of the biocide active substance dossier

Amoeba announces a postponement of the conclusion of the evaluation by Malta of the biocide active substance dossier

Chassieu (France), July 5th, 2021 – 5:45 p.m. – AMOÉBA (FR0011051598 – ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in the development phase, announces that it has received, on June 24th, 2021, a final set of questions from the Maltese Authority which is evaluating the biocidal active substance dossier.

As a reminder, in its press release dated April 6th, 2021, specifying the timetable for the biocidal and phytosanitary regulatory dossiers, the Company estimated that the evaluation report of its “Biocide” dossier by the Maltese Authority could be available by mid-2021.

Considering the time needed to submit the response file, as well as the time needed for the assessment of the response file, the Maltese Authority has committed to finalise the assessment report in the 4th quarter of 2021.

The Company has decided to take advantage of this new series of questions to enrich its dossier by also submitting the results of a laboratory study currently under finalization, based on the European standard EN 136231, which demonstrates an abatement of more than 99% of the legionella level over 96 hours. This efficacy study complements the efficacy data already submitted, strengthening the demonstration of the efficacy of the active substance in continuous injection.